Skip to content

Treatment of cuff tendinopathy with platelet lysis

The effects of platelet lysate therapy on cuff tendinopathy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160422027520N17
Enrollment
40
Registered
2020-04-14
Start date
2020-05-19
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cuff tendinopathy. Unspecified rotator cuff tear or rupture of right shoulder, not specified as traumatic

Interventions

Intervention 1: Intervention group: In this group of patients, 10 ml of blood will be taken by PRP-specific syringe manufactured by Noavaran Salamat Arjang CO. and according to kit protocol, we will s

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Men and women between the ages of 18 and 75 with cuff tendinopathy The availability of individual during the study period

Exclusion criteria

Exclusion criteria: People under the age of 18 and over 75 years Pregnant women or women who are breastfeeding People with malignancy,People with severe heart disease, uncontrolled diabetes mellitus, hemorrhagic diseases, history of anemia, arthritis, fibromyalgia and chronic fatigue syndrome Those linked to acetaminophen or Vicodin or a history of drug misuse History of cortisone injections in the last 6 weeks The use of non-steroidal anti-inflammatory drugs 1 week ago Having hemoglobin less than 11 g / dl and platelet count less than 150000 / mµ The use of inhibitors of platelet aggregation and anti-coagulation such as heparin History of cuff surgery in the last 3 months

Design outcomes

Primary

MeasureTime frame
Determining cuff pain by VAS in all phases of clinical trial. Timepoint: 1 and 3 months after the first injection. Method of measurement: Questionnaire (VAS).;Determination of cuff function by Shoulder Pain and Disability Index (SPADI) in all phases of clinical trial. Timepoint: 1 and 3 months after the first injection. Method of measurement: Questionnaire (SPADI).;Determine the range of cuff motion by manual joiniometry in all phases of clinical trial. Timepoint: 1 and 3 months after the first injection. Method of measurement: Range of motion (Degree).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Yousefi

Tabriz University of Medical Sciences

yousefime@tbzmed.ac.ir+98 41 1336 4665

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026